Biologic therapies for chronic inflammatory bowel disease
M P Martínez-Montiel1, M T Muñoz-Yagüe
1Service of Digestive Diseases, Hospital Universitario 12 de Octubre, Madrid, Spain. pilarmarmon1,2,3@telefónica.net
Revista Espanola De Enfermedades Digestivas
|June 24, 2006
Summary
Biologic therapies like infliximab offer targeted treatment for inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). Research is ongoing for novel treatments to improve patient outcomes and manage disease flares effectively.
Area of Science:
- Gastroenterology and Immunology
- Pharmacology and Therapeutics
Background:
- Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), presents significant management challenges.
- Recent advancements in understanding IBD pathophysiology have spurred the development of targeted biologic therapies.
Purpose of the Study:
- To review the current landscape and future directions of biologic therapies for inflammatory bowel disease.
- To evaluate the efficacy and established roles of existing treatments like infliximab and explore emerging therapeutic strategies.
Main Methods:
- Review of current literature on biologic therapies for CD and UC.
- Analysis of clinical trial data and established treatment guidelines.
- Discussion of novel therapeutic targets and agents in development.
Main Results:
- Infliximab is the established biologic therapy for fistulizing CD and severe UC flare-ups unresponsive to standard treatments.
- Adalimumab serves as an alternative for specific patient groups, though optimal dosing requires further study.
- Anti-integrin therapies face regulatory hurdles, while immunostimulating agents and other biologics show future promise.
Conclusions:
- Biologic therapies, particularly infliximab, have transformed IBD management, offering more specific treatment with potentially fewer side effects.
- Ongoing research into novel agents like anti-CD3 drugs and T-cell inhibitors will further refine therapeutic algorithms for IBD.
- Future strategies may incorporate immunostimulating factors and epithelial repair agents for comprehensive IBD care.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...